Boehringer Ingelheim GmbH and Eli Lilly and Company could soon be looking forward to further expansion of their blockbuster Jardiance beyond diabetes and heart failure after a late-stage trial of the SGLT2 inhibitor in chronic kidney disease (CKD) patients was stopped early due to "clear positive efficacy."
The EMPA-KIDNEY study, the largest SGLT2 inhibitor trial in CKD to date which started enrolling in 2019, included more than...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
